Status:
COMPLETED
Safety of Propofol Sedation ( > 200 mg) for Colonoscopy.
Lead Sponsor:
Showa Inan General Hospital
Conditions:
Safety Issues
Eligibility:
All Genders
20-90 years
Brief Summary
This study examines that the use of \>200 mg of propofol sedation enables patients to drive home safely after outpatient colonoscopy.
Detailed Description
The hospital policy of routine discharge to normal activity 1 hour after propofol mono-sedation for EGD or colonoscopy was approved by the ethics committee of Showa Inan General Hospital in January, 2...
Eligibility Criteria
Inclusion
- subjects who drive home by theirselves after colonoscopy using propofol sedation (\>200 mg)
Exclusion
- Subjects who received emergency procedures
- less than 20 years old pregnant American Society of Anesthesiologists (ASA) class III or IV, overweight (body weight \>100 kg) allergic to the drugs used or its components (soybeans or eggs).
Key Trial Info
Start Date :
January 16 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05213208
Start Date
January 16 2022
End Date
December 31 2024
Last Update
May 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Showa Inan General hospital
Komagane, Nagano, Japan, 399-4191